Organization and Operations - Additional Information (Details) $ / shares in Units, $ in Thousands				12 Months Ended
	Feb. 03, 2021 USD ($) $ / shares shares	Jan. 29, 2021	May 18, 2020 USD ($) shares	Dec. 31, 2021 USD ($) shares	Dec. 31, 2020 USD ($) shares
Subsidiary Sale Of Stock [Line Items]
Shares issued related to acquisition, value			$ 541		$ 541
Net loss				$ 36,794	$ 20,100
Cash, cash equivalents and marketable securities				$ 147,600
Reverse stock split description		On January 29, 2021, the Company effected a reverse stock split of the Company’s common stock on a 48-for-1 basis (the “Reverse Stock Split”).
Reverse stock split conversion ratio		0.020833
Common Stock
Subsidiary Sale Of Stock [Line Items]
Number of shares issued related to acquisition | shares					304,376
Issuance of common stock, shares | shares				8,030,295	705,750
Common Stock | IPO
Subsidiary Sale Of Stock [Line Items]
Issuance of common stock, shares | shares	8,030,295
Share price per share | $ / shares	$ 19.00
Proceeds from issuance initial public offering	$ 152,600
Net proceeds after deducting underwriting discounts and offering expenses	$ 138,500
Common Stock | Underwriters' Option to Purchase Additional Shares
Subsidiary Sale Of Stock [Line Items]
Issuance of common stock, shares | shares	1,030,243
Stock Purchase Agreement | Alvaxa Biosciences, Inc.
Subsidiary Sale Of Stock [Line Items]
Number of shares issued related to acquisition | shares			304,376
Amount paid to settle liabilities assumed			$ 197